HDM1002
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Huadong Medicine · Phase 1 · Status n/r · Enrollment 30
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatin | n/r | n/r | n/r | n/r |
Not shown
- HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatin: endpoint not reported